WEBER, Pavel, Hana MELUZÍNOVÁ, Dana WEBEROVÁ, Petronela AMBROŠOVÁ, Pavel KUKLÍNEK, Hana MATĚJOVSKÁ KUBEŠOVÁ, Katarína BIELAKOVÁ and Marie ČERNÁ. Přínos stanovení GADA u T1D a LADA (Benefit determination GADA in LADA and T1D). In In: Abstrakta, XLVIII. Diabetologické dny, Luhačovice,. 2012. ISSN 1802-1891.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Přínos stanovení GADA u T1D a LADA
Authors WEBER, Pavel (203 Czech Republic, guarantor, belonging to the institution), Hana MELUZÍNOVÁ (203 Czech Republic, belonging to the institution), Dana WEBEROVÁ (203 Czech Republic, belonging to the institution), Petronela AMBROŠOVÁ (703 Slovakia, belonging to the institution), Pavel KUKLÍNEK (203 Czech Republic), Hana MATĚJOVSKÁ KUBEŠOVÁ (203 Czech Republic, belonging to the institution), Katarína BIELAKOVÁ (703 Slovakia, belonging to the institution) and Marie ČERNÁ (203 Czech Republic).
Edition In: Abstrakta, XLVIII. Diabetologické dny, Luhačovice, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/12:00063456
Organization unit Faculty of Medicine
ISSN 1802-1891
Keywords (in Czech) diabetes mellitus 1 - LADA - GADA - IA-2 - HLA–DRB1 genotip - inzulinoterapie
Keywords in English type 1 diabetes mellitus (T1D) - Late Autoimmune Diabetes of Adults (LADA) - GADA - IA-2 - HLA–DRB1 genotype - insulin therapy
Changed by Changed by: prof. MUDr. Pavel Weber, CSc., učo 37287. Changed: 2/2/2013 22:50.
Abstract
The presence of elevated GADA identifies patients unequivocally suitable for early insulin therapy. Our observations and experiences confirm that GADA can be found increased after more than 10–20 years duration of DM, although in decreasing trend.
PrintDisplayed: 24/5/2024 00:29